M. Patel

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Manesh R Patel, Manesh Raman Patel, M R Patel, Manesh R. Patel, Manesh Patel
Publication record
719 papers · 45,425 citations · H-index 99

PAPERS

Influence of Obesity on Coronary Artery Disease and Clinical Outcomes in the ADVANCE Registry
202311 citationsauthor #25
Deferred Testing in Stable Outpatients With Suspected Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized Clinical Trial.
202310 citationsauthor #8
Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
202318 citationsauthor #7
Splanchnic Nerve Modulation Effects on Surrogate Measures of Venous Capacitance
20232 citationsauthor #15
Anonymous Comparison of Various Angiography-Derived Fractional Flow Reserve Software With Pressure-Derived Physiological Assessment.
202351 citationsauthor #17
Evidence Generation for Novel Cardiovascular Devices-Putting the Horse Back in Front of the Cart.
20231 citationsauthor #2
Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
202356 citationsauthor #5
Clinical spectrum of COVID-19 complications in young adults: combined analysis of the American Heart Association COVID-19 Cardiovascular Disease Registry and the Outcomes Registry for Cardiac Conditions in Athletes
20233 citationsauthor #8
Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease
202368 citationsauthor #6
Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum.
202354 citationsauthor #7
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
202348 citationsauthor #5
Non-COVID-19 cardiovascular pathology from return-to-play screening in college athletes after COVID-19
20234 citationsauthor #8
Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation.
202343 citationsauthor #10
DESIGN AND INITIAL RESULTS OF AN ANGIOGRAPHIC CORE LAB FROM THE VOYAGER PAD TRIAL
20230 citationsauthor #21
Coronary Volume to Left Ventricular Mass Ratio in Patients With Hypertension.
20234 citationsauthor #4
Clinical and Cost Implications of Deferred Testing in Low-risk Patients with Stable Chest Pain: A Simulation Using the PROMISE Trial.
20232 citationsauthor #6
Association of race and in‐hospital outcomes following acute pulmonary embolism: A retrospective cohort study
20233 citationsauthor #5
Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure – mechanism of action (SPONGE‐HF)
20235 citationsauthor #15
The Cardiac Effects of COVID-19 on Young Competitive Athletes: Results from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA)
20239 citationsauthor #6
Rationale and Design of the ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) Study
202316 citationsauthor #11
Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
20229 citationsauthor #5
SPLANCHNIC NERVE MODULATION EFFECTS ON SURROGATES MEASURES OF VENOUS COMPLIANCE
20220 citationsauthor #12
Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients.
20227 citationsauthor #9
Reduced dose, but not reduced risk: rates of inappropriate apixaban dose reduction and stroke and bleeding incidence
20222 citationsauthor #14
Rivaroxaban in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Bypass Surgery with Venous and Prosthetic Conduits.
202214 citationsauthor #20
Abstract 12361: Efficacy and Safety of NOACs vs. Warfarin Across the Continuous Range of Body Mass Index and Body Weight: Insights From COMBINE-AF
20220 citationsauthor #12
Challenges and Opportunities in Reversing Concerning Trends in Cardiovascular Disease and Life Expectancy
20221 citationsauthor #2
Cardiac Troponin Testing as a Component of Return to Play Cardiac Screening in Young Competitive Athletes Following SARS‐CoV‐2 Infection
20224 citationsauthor #8
Economic Outcomes with Anatomic versus Functional Diagnostic Testing for Coronary Artery Disease
20220 citationsauthor #7
Initial Thoracic Endovascular Aortic Repair vs Medical Therapy for Acute Uncomplicated Type B Aortic Dissection.
202221 citationsauthor #13
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort
202237 citationsauthor #13
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
2022203 citationsauthor #12
A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia
202226 citationsauthor #10
Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).
20223 citationsauthor #15
RIVAROXABAN REDUCES HOSPITALIZATIONS FOR THROMBOEMBOLIC EVENTS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE AFTER REVASCULARIZATION IN THOSE WITH AND WITHOUT CHRONIC KIDNEY DISEASE
20220 citationsauthor #3
Abstract 9499: Clinical Outcomes With Initial Thoracic Endovascular Aortic Repair versus Initial Medical Therapy for Acute Uncomplicated Type B Aortic Dissection in the United States
20220 citationsauthor #13
The Clinical Problem of Pelvic Venous Disorders.
20224 citationsauthor #6
Understanding Study Drug Discontinuation Through EUCLID
20224 citationsauthor #11
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD
202210 citationsauthor #5
Abstract 12197: Causes of Death in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization: Insights From Voyager Pad
20220 citationsauthor #4
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
20228 citationsauthor #6
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
2022206 citationsauthor #7
Early TEVAR for Uncomplicated Type B Aortic Dissection Does Not Improve Outcomes in a National Sample
20220 citationsauthor #11
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.
202223 citationsauthor #6
INTRAVASCULAR BLOOD VOLUME ANALYSIS AND HEMODYNAMIC MEASURES OF VASCULAR COMPLIANCE IN PATIENTS HOSPITALIZED FOR HEART FAILURE
20220 citationsauthor #4
Physician judgement in predicting obstructive coronary artery disease and adverse events in chest pain patients
20223 citationsauthor #7
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
202211 citationsauthor #5
BENEFITS OF RIVAROXABAN AFTER LOWER EXTREMITY REVASCULARIZATION FOR SYMPTOMATIC PERIPHERAL ARTERY DISEASE ARE CONSISTENT WITH AND WITHOUT BACKGROUND STATIN THERAPY
20220 citationsauthor #4
Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors.
202236 citationsauthor #8
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD
20227 citationsauthor #4
Impact of risk factor control on peripheral artery disease outcomes and health disparities
20223 citationsauthor #12
WALKING IMPAIRMENT IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERY DISEASE AFTER LOWER EXTREMITY REVASCULARIZATION
20220 citationsauthor #4
Abstract 9928: Risk Stratification for Amputation in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD
20220 citationsauthor #3
TOTAL CARDIOVASCULAR AND LIMB EVENTS WITH TICAGRELOR AND CLOPIDOGREL IN PATIENTS WITH SYMPTOMATIC PAD IN THE EUCLID TRIAL
20220 citationsauthor #3
Cardiovascular and Limb Events Following Endovascular Revascularization Among Patients ≥65 Years Old: An American College of Cardiology PVI Registry Analysis
202219 citationsauthor #10
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease
20227 citationsauthor #3
The role of extended reality for planning coronary artery bypass graft surgery
20223 citationsauthor #4
NOAC USE IS SAFE AND EFFECTIVE FOR PATIENTS WITH ATRIAL FIBRILLATION AND REDUCED RENAL FUNCTION: RESULTS FROM COMBINE-AF
20220 citationsauthor #6
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
2022113 citationsauthor #76
Abstract 12458: Limb and Cardiovascular Events at 6 Months Among CLTI Patients Receiving Routine Care at BEST-CLI Sites: An Interim Report From the BEST-Registry
20222 citationsauthor #2
Coronary volume to left ventricular mass ratio in patients with diabetes mellitus.
202210 citationsauthor #5
Incidence and risk factors for major bleeding events in atrial fibrillation patients on direct oral anticoagulant therapy: data from the National Patient-Centered Clinical Research Network
20220 citationsauthor #15
Cardiovascular Outcomes in Collegiate Athletes Following SARS-CoV-2 Infection: 1-year Follow-up from the Outcomes Registry for Cardiac Conditions in Athletes.
202220 citationsauthor #7
Abstract 10240: Lower May Not Be Better: Systolic Blood Pressure and Risk of Major Adverse Limb Events in Patients With Symptomatic Peripheral Artery Disease After Revascularization: Insights From Voyager Pad
20220 citationsauthor #4
Lipid-Lowering Therapy in Women of Childbearing Age: a Review and Stepwise Clinical Approach
20223 citationsauthor #6
One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease
202215 citationsauthor #5
Abstract 10889: Unplanned Limb Revascularization With Rivaroxaban versus Placebo in Patients With Critical Limb Ischemia After Endovascular and Surgical Treatment: Insights From Voyager Pad
20220 citationsauthor #2
1-Year Outcomes of Blinded Physiological Assessment of Residual Ischemia After Successful PCI: DEFINE PCI Trial.
202261 citationsauthor #1
Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation
20225 citationsauthor #9
Echocardiographic Reporting of the Aorta in Young Competitive Athletes.
20222 citationsauthor #7
Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement.
20210 citationsauthor #6
Acute cardiovascular hospitalizations and illness severity before and during the COVID‐19 pandemic
20218 citationsauthor #6
Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.
20217 citationsauthor #16
Survival and Causes of Death Among Veterans With Lower Extremity Revascularization With Paclitaxel‐Coated Devices: Insights From the Veterans Health Administration
202126 citationsauthor #13
Efficacy of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease With Venous and Prosthetic Surgical Bypass Conduits: Insights from the VOYAGER PAD Trial
20211 citationsauthor #5
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials
20216 citationsauthor #19
Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease Questionnaire
202110 citationsauthor #4
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial.
20216 citationsauthor #4
Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Non-ST-Segment-Elevation Myocardial Infarction for Intensive Care Unit Admission.
20217 citationsauthor #8
Atrial Branch Coronary Artery Stenosis as a Mechanism for Atrial Fibrillation.
202116 citationsauthor #7
Phenome‐Wide Association Study of Severe COVID‐19 Genetic Risk Variants
202113 citationsauthor #6
The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?
20216 citationsauthor #4
Evaluation of Women and Underrepresented Racial and Ethnic Group Representation in a General Cardiology Fellowship After a Systematic Recruitment Initiative
202130 citationsauthor #7
Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA)
202162 citationsauthor #5
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial
20217 citationsauthor #14
TCT-157 Intra-Aortic Unloading Before Reperfusion Reduces Infarct Size in a Preclinical Model of STEMI
20210 citationsauthor #5
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID
202121 citationsauthor #13
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations
202142 citationsauthor #7
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
202116 citationsauthor #4
The Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization: Rationale and Design of the PRECISE Trial.
202119 citationsauthor #5
EFFICACY AND SAFETY OF RIVAROXABAN IN ELDERLY PATIENTS WITH SYMPTOMATIC PAD UNDERGOING REVASCULARIZATION: INSIGHTS FROM VOYAGER PAD
20212 citationsauthor #5
TCT-399 Relationship Between Coronary CT Angiography–Derived Fractional Flow Reserve and Clinical Outcomes in Patients With and Without Diabetes
20210 citationsauthor #23
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
202136 citationsauthor #13
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD
202130 citationsauthor #5
Renal Denervation for Patients With Heart Failure: Making a Full Circle.
202120 citationsauthor #4
EFFICACY AND SAFETY OF LOW-DOSE RIVAROXABAN IN SYMPTOMATIC PAD PATIENTS UNDERGOING REVASCULARIZATION CURRENTLY SMOKING: INSIGHTS FROM VOYAGER PAD
20211 citationsauthor #3
Association between Economic and Arrhythmic Burden of Paroxysmal Atrial Fibrillation in Patients with Cardiac Implanted Electronic Devices.
20216 citationsauthor #8
Trans-lesional fractional flow reserve gradient as derived from coronary CT improves patient management: ADVANCE registry☆
202134 citationsauthor #26
National trends in repair for type B aortic dissection
20217 citationsauthor #7
The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization.
202110 citationsauthor #7

TIMELINE

1989 1 citations

1993 1 citations

1995 142 citations

2002 18 citations

2003 3 citations

2004 82 citations

2005 1,125 citations

2006 2,196 citations

2007 645 citations

2008 1,203 citations

2009 2,057 citations

2010 2,778 citations

2011 8,421 citations

2012 2,773 citations

2013 2,563 citations

2014 4,700 citations

2015 2,698 citations

2016 2,453 citations

2017 2,705 citations

2018 1,753 citations

2019 2,555 citations

2020 2,044 citations

2021 1,128 citations

2022 902 citations

2023 408 citations

Unknown 0 citations

M. Patel

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT